Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 178 results.
LastUpdate Updated on 21/02/2026 [07:40:00]
pdfxls
Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days
previousPage Results 175 to 178 of 178  

COMPOSITIONS AND METHODS FOR IBD PATIENTS USING STOOL-DERIVED EUKARYOTIC NUCLEIC ACIDS

Publication No.:  AU2024213250A1 07/08/2025
Applicant: 
GENEOSCOPY INC
GENEOSCOPY, INC
AU_2024213250_PA

Absstract of: AU2024213250A1

The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).

HOST TRANSCRIPTOME FECAL BIOMARKERS FOR GASTROINTESTINAL INFLAMMATORY DISORDERS

Publication No.:  WO2025163643A1 07/08/2025
Applicant: 
YEDA RES AND DEVELOPMENT CO LTD [IL]
SHEBA IMPACT LTD [IL]
TRACELLS LTD [IL]
YEDA RESEARCH AND DEVELOPMENT CO. LTD,
SHEBA IMPACT LTD,
TRACELLS LTD
WO_2025163643_A1

Absstract of: WO2025163643A1

The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.

消化器疾患の治療

Nº publicación: JP2025116257A 07/08/2025

Applicant:

アイアンウッドファーマシューティカルズインコーポレイテッド

JP_2025116257_A

Absstract of: JP2024015204A

To provide peptides, compositions and methods for treating gastrointestinal disorders.SOLUTION: The invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.SELECTED DRAWING: None

traducir